{"id":"brinzolamide-ophthalmic-suspension","safety":{"commonSideEffects":[{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Ocular discomfort or irritation"},{"rate":null,"effect":"Taste perversion"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brinzolamide inhibits carbonic anhydrase II in the ciliary body of the eye, which decreases the secretion of aqueous humor. By reducing aqueous humor production, the drug lowers intraocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension management. The ophthalmic suspension formulation allows direct topical delivery to the eye.","oneSentence":"Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, thereby lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:12.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma"}]},"trialDetails":[{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT04944290","phase":"PHASE3","title":"To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2021-05-28","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":447},{"nctId":"NCT05022004","phase":"PHASE3","title":"A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2021-12-20","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":599},{"nctId":"NCT01722604","phase":"PHASE3","title":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2012-01","conditions":"Glaucoma, Open Angle or Ocular Hypertension","enrollment":258},{"nctId":"NCT03896633","phase":"PHASE1, PHASE2","title":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2018-02-28","conditions":"Glaucoma, Open Angle or Ocular Hypertension","enrollment":637},{"nctId":"NCT04024072","phase":"PHASE3","title":"To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2019-06-24","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":495},{"nctId":"NCT04523844","phase":"NA","title":"Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections","status":"COMPLETED","sponsor":"General Hospital of Athens Elpis","startDate":"2020-05-11","conditions":"Eye Diseases, Injection Complication, Intraocular Pressure","enrollment":47},{"nctId":"NCT02512042","phase":"PHASE3","title":"Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-04","conditions":"Glaucoma","enrollment":973},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT02339584","phase":"PHASE3","title":"Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-04-14","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":493},{"nctId":"NCT02770248","phase":"PHASE4","title":"24-hr Intraocular Pressure Control With SIMBRINZA ®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-05-23","conditions":"Glaucoma","enrollment":162},{"nctId":"NCT03494257","phase":"NA","title":"Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2017-09-04","conditions":"Cataract, Intraocular Pressure","enrollment":62},{"nctId":"NCT02325518","phase":"PHASE4","title":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2014-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":218},{"nctId":"NCT00314171","phase":"PHASE3","title":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":437},{"nctId":"NCT00061516","phase":"PHASE3","title":"Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":78},{"nctId":"NCT00314158","phase":"PHASE3","title":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-11","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":523},{"nctId":"NCT02140060","phase":"PHASE2","title":"6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":327},{"nctId":"NCT01937312","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":282},{"nctId":"NCT01937299","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":307},{"nctId":"NCT01978600","phase":"PHASE4","title":"Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":89},{"nctId":"NCT01312402","phase":"PHASE4","title":"Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome","status":"COMPLETED","sponsor":"Akron Children's Hospital","startDate":"2011-01","conditions":"Infantile Nystagmus Syndrome","enrollment":5},{"nctId":"NCT01357616","phase":"PHASE3","title":"Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-11","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":328},{"nctId":"NCT01309204","phase":"PHASE3","title":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1184},{"nctId":"NCT01310777","phase":"PHASE3","title":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":771},{"nctId":"NCT01340014","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT00759941","phase":"PHASE4","title":"A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-10","conditions":"Glaucoma","enrollment":86},{"nctId":"NCT01426867","phase":"PHASE2","title":"A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":103},{"nctId":"NCT01297920","phase":"PHASE3","title":"Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1062},{"nctId":"NCT00961649","phase":"PHASE2","title":"Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2009-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":195},{"nctId":"NCT01297517","phase":"PHASE3","title":"Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1001},{"nctId":"NCT00800540","phase":"PHASE4","title":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT00767494","phase":"PHASE3","title":"Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":17},{"nctId":"NCT00767481","phase":"PHASE3","title":"1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":6},{"nctId":"NCT00527501","phase":"PHASE2","title":"IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-08","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":136},{"nctId":"NCT00121147","phase":"NA","title":"Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan","status":"COMPLETED","sponsor":"Hermann Eye Center","startDate":"2003-09","conditions":"Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Brinzolamide ophthalmic suspension","genericName":"Brinzolamide ophthalmic suspension","companyName":"Sun Pharmaceutical Industries Limited","companyId":"sun-pharmaceutical-industries-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, thereby lowering intraocular pressure. Used for Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}